Pfizer Finalizes $2.3B Bextra Off-Label Marketing Deal

Law360, New York (September 2, 2009, 5:13 PM EDT) -- Pfizer Inc. will pay $2.3 billion and one of its subsidiaries will plead guilty to a criminal charge to settle claims that the drug giant improperly marketed the discontinued anti-inflammatory drug Bextra and three other medicines, federal regulators announced Wednesday, marking the largest such settlement on record.

Pfizer first reported that it had reached the settlement in principle in a January filing with the U.S. Securities and Exchange Commission.

One unit of Pfizer, Pharmacia & Upjohn Company Inc., agreed to plead guilty to one criminal count...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.